Clinical pharmacy services evaluation across five pediatric respiratory disease cases: A comprehensive study

doi:10.5246/jcps.2025.07.051

Abstract

Abstract:

The aim of this study is to investigate how clinical pharmacists can optimize drug use for pediatric patients with respiratory diseases. We extracted etiological, symptomatic, and medication-related information from patient medical records. The rationality of each patient’s medication regimen was evaluated using relevant tools, including DXY, Medication Assistant Software (mobile version), MCDEX Software (mobile version), and literature from databases such as VIP and CNKI. By considering the patients’ age, prescribed medication regimens, and disease characteristics, we identified key aspects and precautions for pharmaceutical care. Pharmacists provided tailored pharmaceutical care and medication education based on each patient’s specific age, treatment plan, and illness profile. Through active involvement in personalized medication management, pharmacists can offer individualized drug services, enhancing both the safety and effectiveness of treatments for pediatric patients.

Key words: Children, Respiratory system, Medication services, Clinical pharmacist

Supporting:

Siyi Han, Yanan Wei, Naiyue Shi, Yuhang Wang, Linlin Lai. Clinical pharmacy services evaluation across five pediatric respiratory disease cases: A comprehensive study[J]. Journal of Chinese Pharmaceutical Sciences, 2025, 34(7): 682-690.

Figures/Tables 1

References 20

[1]	Han, Y.X.; Huang, Y.Y.; Zhao, R.L. Analysis of 1188 drug consultation records in children. Chin. J. Clin. Pharm. 2020, 29, 136–139.
[2]	Sharland, M.; Gandra, S.; Huttner, B.; Moja, L.; Pulcini, C.; Zeng, M.; Mendelson, M.; Cappello, B.; Cooke, G.; Magrini, N.; EML Expert Committee and Antibiotic Working Group. Encouraging AWaRe-ness and discouraging inappropriate antibiotic use-the new 2019 Essential Medicines List becomes a global antibiotic stewardship tool. Lancet Infect. Dis. 2019, 19, 1278–1280.
[3]	Ni, X. Community-acquired pneumonia diagnosis and treatment norms for children (2019 edition). Clin. Educ. Gen. Pract. 2019, 17, 771–777.
[4]	Kimberlin, D.W.; Brady, M.T.; Jackson, M.A.; Long, S. Red book: 2015 report of the committee on infectious diseases. 30th ed. EIk Grove Village: American Academy of Pediatrics. 2015, 883, 889.
[5]	Young, T.E. Neofax 2011, 24th ed. New York: Thomson Reuters. 2011, 16–17.
[6]	Zhao, S.Y.; Chen, Z.M.; Liu, H.M.; Zhao, D.Y.; Hong, J.G.; Lu, Q. Highlights of the National Health Commission’s Guidelines for the Diagnosis and Treatment of Mycoplasma pneumoniae in Children (2023 Edition). J. Clin. Paediatr. 2023, 41, 224–228.
[7]	Tang, J.Y.; Wang, Q.; Wu, S.J.; Xu, H.F.; Zhang, S.H. Zhang, G. Efficacy and safety of different-course intravenous azithromycin treatments for mycoplasmal pneumonia in children: a Meta-analysis. China Pharmacist. 2020, 23, 97–100.
[8]	Stokholm, J.; Chawes, B.L.; Vissing, N.H.; Bjarnadóttir, E.; Pedersen, T.M.; Vinding, R.K.; Schoos, A.M M.; Wolsk, H.M.; Thorsteinsdóttir, S.; Hallas, H.W.; Arianto, L.; Schjørring, S.; Krogfelt, K.A.; Fischer, T.K.; Pipper, C.B.; Bønnelykke, K.; Bisgaard, H. Azithromycin for episodes with asthma-like symptoms in young children aged 1–3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2016, 4, 19–26.
[9]	Li, W.J.; Lu, M.Q.; Xu, A.L.; Xi, X.Y. Comparison and thinking of drug dosage forms for children of different ages at home and abroad. Chin. Hosp. Pharm. J. 2019, 39, 2236–2239.
[10]	Wei, K.X.; Luo, J. Research progress on medication education of inhaled preparation. Guangxi Med. J. 2022, 44, 1661–1663, 1689.
[11]	Giraud, V.; Allaert, F.A.; Roche, N. Inhaler technique and asthma: Feasability and acceptability of training by pharmacists. Respir. Med. 2011, 105, 1815–1822.
[12]	Xue, J.Y.; Zhang, X.Y.; Cheng, J. Application effect of psychological nursing in emergency pediatric intravenous infusion nursing. Clin. Res. Pra. 2022, 7, 160–162.
[13]	Qiu, K.F.; He, Z.C.; Chen, Z.P.; Zhu. J.H.; Zheng, Z.H.; Wu, J.Y. Interpretation of the group standard "Code for evidence-based evaluation of over-the-counter medication". Phram. Today. 2021, 31, 811–814.
[14]	Zha, L.; Wang, C.J.; Ji, J.J. Investigation on the off-label drug use in pediatric outpatients based on evidence-based pharmacy. Pract. Pharm. Clin. Remed. 2019, 22, 1091–1095.
[15]	Ramirez, J.; Guarner, F.; Bustos Fernandez, L.; Maruy, A.; Sdepanian, V.L.; Cohen, H. Antibiotics as major disruptors of gut microbiota. Front. Cell. Infect. Microbiol. 2020, 10, 572912.
[16]	Zheng, Y.J.; Wu, Q.B.; Fang, F.; Chen, J.; Shang, Y.X.; Fu, Z.; Zhang, L.; Lu, M.; Cao, L.; Cui. H.; Peng, S.; Qu, S.Q.; Yang, Y.H.; Shen, K.L. Expert consensus on the diagnosis, treatment and prevention of antibiotic-associated diarrhea in children. Chin. J. Appl. Clin. Pediatr. 2021, 36, 424–430.
[17]	Fan, Z.; He, J.F.; Huang, J.; Chen, B.B. Correlation of vitamin D levels with recurrent respiratory infections and immune function in children. Chin. J. Matern. Child Health Care. 2023, 38, 1033–1036.
[18]	Kong, X.Y.; Chen, Q.; Wu, X.; Bian, H.M.; Li, Y. The research progress of interaction between Chinese and western medicine combination. J. Nanjing Univ. Tradit. Chin. Med. 2018, 34, 5–11.
[19]	Hu, L.; Ma, Z, Y.; Lv, Y. Correlation between antibiotic use and parental anxiety and depression in children with respiratory diseases. Chin. J. Lab. Diagn. 2022, 26, 983–987.
[20]	Yu, S.; Li, Y.; Zhong, Z. Investigation on knowledge, attitude and practice about antibiotic among 1445 children’s parents. Matern. Child Health Care China. 2022, 37, 3980–3983.